Medizone Home
×

Epirus expands biosimilar pipeline and capabilities

Epirus Biopharmaceuticals, Inc., announced an agreement for the acquisition of Bioceros Holding B.V., enabling Epirus to expand its biosimilar pipeline and vertically integrate product development capabilities.

From the Bioceros platform, Epirus will expand its pipeline with the addition of three preclinical product candidates: BOW080, a proposed biosimilar to eculizumab (reference biologic Soliris); BOW090, a proposed biosimilar to ustekinumab (reference biologic Stelara); and BOW100, a proposed biosimilar to golimumab (reference biologic Simponi).  Soliris, marketed by Alexion Pharmaceuticals, is currently indicated to treat ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).  Simponi and Stelara are marketed by Janssen Pharmaceuticals and indicated in inflammatory and immune mediated disorders.

These three new pipeline assets represent a global growth opportunity for Epirus in targeting reference biologics with estimated 2020 peak sales of $12 billion.  The platform also enables future pipeline growth opportunities for Epirus.  The anticipated filing dates for the three new pipeline products are 2020 for BOW080, 2021 for BOW090 and 2022 for BOW100.

Source: Epirus Press release